Japan's Medical And Biologic Laboratories To Expand CTL Immunotherapy In China
This article was originally published in PharmAsia News
Executive SummaryAichi-based Medical and Biological Laboratories plans to commence clinical study for immunotherapy using cytotoxic T lymphocyte in China in September
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.